Patents Assigned to Motac Neuroscience Limited
  • Treatment of motor fluctuations
    Patent number: 9668995
    Abstract: The invention relates to the use of compounds that enhance 5-hydroxytryptamine 1a receptor activity, or activation (e.g. a selective 5-hydroxytryptamine 1a receptor agonists) for preventing or reducing motor fluctuations associated with dopamine replacement therapy.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: June 6, 2017
    Assignee: Motac Neuroscience Limited
    Inventors: Jonathan Brotchie, Michael Hill
  • Medicaments
    Patent number: 8389555
    Abstract: A compound of formal (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: March 5, 2013
    Assignee: Motac Neuroscience Limited
    Inventors: Holger Stark, Jukka Matti Leppanen, Britta Caroline Sasse, Oliver Saur, Tim Kottke, Michael Peter Hill
  • Treatment of dyskinesia
    Patent number: 8198294
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: June 12, 2012
    Assignee: Motac Neuroscience Limited
    Inventor: Jonathan Brotchie
  • Treatment of Motor Fluctuations
    Publication number: 20110178178
    Abstract: The invention relates to the use of compounds that enhance 5-hydroxytryptamine 1a receptor activity, or activation (e.g. a selective 5-hydroxytryptamine 1a receptor agonists) for preventing or reducing motor fluctuations associated with dopamine replacement therapy.
    Type: Application
    Filed: March 31, 2011
    Publication date: July 21, 2011
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventors: Jonathan Brotchie, Michael Hill
  • Treatment of dyskinesia
    Patent number: 7935718
    Abstract: The present invention relates to the use of compounds that enhance H3-histamine receptor activity, or activation (e.g. H3-histamine receptor agonists) for the treatment of dyskinesia. The compounds are particularly useful for treating dyskinesia associated with parkinsonian therapy.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: May 3, 2011
    Assignee: Motac Neuroscience Limited
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman
  • Medicaments
    Publication number: 20110046153
    Abstract: A compound of formal (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.
    Type: Application
    Filed: October 28, 2008
    Publication date: February 24, 2011
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventors: Holger Stark, Jukka Matti Leppanen, Britta Caroline Sasse, Oliver Saur, Tim Kottke, Michael Peter Hill
  • Treatment of dyskinesia
    Publication number: 20100184797
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Application
    Filed: August 31, 2009
    Publication date: July 22, 2010
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventor: Jonathan Brotchie
  • Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
    Publication number: 20050261282
    Abstract: The present invention relates to compounds, related to 2,3 benzodiazepines, of general formula (I), such as Tofisopam, Girisopam or Nerisopam, for use in the treatment of dyskinesia. The dyskinesia may arise as a side-effect of a therapy for pakinsonism.
    Type: Application
    Filed: September 11, 2003
    Publication date: November 24, 2005
    Applicant: Motac Neuroscience Limited Williams House
    Inventors: Alan Crossman, Michael Hill, Jonathan Brotchie
  • Treatment of dyskinesia
    Publication number: 20050245587
    Abstract: The present invention relates to the use of compounds that enhance H3-histamine receptor activity, or activation (e.g. H3-histamine receptor agonists) for the treatment of dyskinesia. The compounds are particularly useful for treating dyskinesia associated with parkinsonian therapy.
    Type: Application
    Filed: October 28, 2004
    Publication date: November 3, 2005
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman
  • Treatment of dyskinesia
    Publication number: 20050009856
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Application
    Filed: April 7, 2004
    Publication date: January 13, 2005
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventor: Jonathan Brotchie
  • Treatment of dyskinesia
    Patent number: 6740659
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: May 25, 2004
    Assignee: Motac Neuroscience Limited
    Inventor: Jonathan Brotchie